Escugen Biotechnology

Escugen Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary Escu-ADC and bispecific antibody platforms to engineer high-affinity biologics with enhanced therapeutic windows. Its lead candidate, ESG-401, is a TROP2-directed antibody-drug conjugate (ADC) currently in Phase 2 clinical trials for triple-negative breast cancer and other solid tumors. Escugen's pipeline also includes bispecific antibodies targeting the PD-L1/4-1BB pathway and monoclonal antibodies against Claudin 18.2. By integrating advanced protein engineering with robust manufacturing capabilities, Escugen aims to deliver transformative treatments for patients with advanced malignancies.